{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:43:57Z","timestamp":1789537437185,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00586","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T02:42:43Z","timestamp":1583721763000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":72,"title":["Primary and Secondary Immunodeficiency Diseases in Oncohaematology: Warning Signs, Diagnosis, and Management"],"prefix":"10.3389","volume":"10","author":[{"given":"Silvia","family":"S\u00e1nchez-Ram\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arancha","family":"Berm\u00fadez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Ignacio","family":"Gonz\u00e1lez-Granado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Rodr\u00edguez-Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Soler-Palac\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ID-Signal Onco-Haematology Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1157\/13075699","article-title":"Directory of diagnostic tests in primary immunodeficiencies","volume":"33","author":"Espanol","year":"2005","journal-title":"Allergol Immunopathol (Madr)"},{"key":"B2","unstructured":"Diagn\u00f3stico de las inmunodeficiencias primarias8192\n            Garc\u00edaMart\u00ednez J\n            Santos-D\u00edezL\n            DopazoL\n          Protoc diagn Ter pediatr12013"},{"key":"B3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s10875-017-0464-9","article-title":"International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity","volume":"38","author":"Picard","year":"2018","journal-title":"J Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.1016\/j.jaci.2009.08.040","article-title":"Secondary immunodeficiencies, including HIV infection","volume":"125","author":"Chinen","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10875-013-9954-6","article-title":"Attending to warning signs of primary immunodeficiency diseases across the range of clinical practice","volume":"34","author":"Costa-Carvalho","year":"2014","journal-title":"J Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3389\/fimmu.2016.00365","article-title":"Cancers related to immunodeficiencies: update and perspectives","volume":"7","author":"Mortaz","year":"2016","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1006\/clim.2002.5241","article-title":"Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study","volume":"104","author":"Plebani","year":"2002","journal-title":"Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1365-2249.2009.04023.x","article-title":"Immunodeficiencies","volume":"158","author":"Ballow","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12026-011-8241-y","article-title":"Global study of primary immunodeficiency diseases (PI)\u2013diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation","volume":"51","author":"Modell","year":"2011","journal-title":"Immunol res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12931-018-0923-8","article-title":"Primary immunodeficiency diseases in lung disease: warning signs, diagnosis and management","volume":"19","author":"Soler-Palac\u00edn","year":"2018","journal-title":"Respir Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1182\/blood-2014-06-583260","article-title":"Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment","volume":"124","author":"Seidel","year":"2014","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1590\/S1806-37132009001000010","article-title":"Primary immunodeficiency diseases: relevant aspects for pulmonologists","volume":"35","author":"Roxo Junior","year":"2009","journal-title":"J bras pneumol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e22420","DOI":"10.1002\/jcla.22420","article-title":"Age-specific pediatric reference ranges for immunoglobulins and complement proteins on the optilite","volume":"30","author":"Garcia-Prat","year":"2018","journal-title":"J Clin Lab Anal"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21728","article-title":"Extended immunophenotyping reference values in a healthy pediatric population","author":"Garcia-Prat","year":"2018","journal-title":"Cytometry B Clin cytom"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3205\/ctt-2010-en-000077.01","article-title":"Hematopoietic cell transplantation for treatment of primary immune deficiencies","author":"Burroughs","year":"2010","journal-title":"Cell ther transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.yapd.2010.08.005","article-title":"Therapeutic use of immunoglobulins","volume":"57","author":"Stiehm","year":"2010","journal-title":"Adv pediatr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/cei.12915","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach","volume":"188","author":"Jolles","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.7861\/clinmedicine.16-6-571","article-title":"Secondary antibody deficiency - causes and approach to diagnosis","volume":"16","author":"Srivastava","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin microbiol infect"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/bcp.13548","article-title":"Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome","volume":"84","author":"Bonanni","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.coi.2016.09.003","article-title":"Targeting B cells in treatment of autoimmunity","volume":"43","author":"Franks","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3389\/fimmu.2016.00317","article-title":"Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy","volume":"7","author":"Sanchez-Ramon","year":"2016","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J autoimmun"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jaci.2011.08.008","article-title":"Effect of rituximab on human in vivo antibody immune responses","volume":"128","author":"Pescovitz","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","article-title":"Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies\u2013a prospective, multi-national study","volume":"26","author":"Gardulf","year":"2006","journal-title":"J Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s40265-013-0094-3","article-title":"Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review","volume":"73","author":"Lingman-Framme","year":"2013","journal-title":"Drugs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.transci.2012.03.022","article-title":"Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases","volume":"46","author":"Haddad","year":"2012","journal-title":"Transfus apher sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13223-015-0092-y","article-title":"Health-related quality of life in patients with primary immunodeficiency disease","volume":"11","author":"Jiang","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2249.2009.04027.x","article-title":"Subcutaneous immunoglobulin: opportunities and outlook","volume":"158","author":"Misbah","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/SMJ.0b013e3181eba6ea","article-title":"Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G","volume":"103","author":"Berger","year":"2010","journal-title":"South Med J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2147\/PPA.S123363","article-title":"A cohort of french pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions?","volume":"11","author":"Pasquet","year":"2017","journal-title":"Patient prefer adherence"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00586\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T02:42:46Z","timestamp":1583721766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00586\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,26]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2019.00586"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00586","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,26]]},"article-number":"586"}}